Cargando...
Considerations for the US health-system pharmacist in a world of biosimilars
As numerous biosimilar products are forecast to enter the US market in the coming years, health-system pharmacists will be faced with novel challenges while incorporating them into clinical practice. The current regulatory approval framework and guidance from the US Food and Drug Administration do n...
Gardado en:
| Publicado en: | Drugs Context |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioExcel Publishing Ltd
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7048155/ https://ncbi.nlm.nih.gov/pubmed/32158487 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.2019-12-1 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|